Belgo-Dutch biotech Galapagos NV and U.S. partner Gilead Sciences Inc. will discontinue late-stage trials testing their experimental drug ziritaxestat in patients with pulmonary fibrosis.
Merck KGaA’s drug development program suffered a setback with the company’s most important experimental medicine as the cancer treatment bintrafusp alfa, being jointly developed by GlaxoSmithKline, failed early in a lead trial.
FRANKFURT (Reuters) – AstraZeneca’s top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, the British drugmaker said on Saturday. A study with patients diagnosed early enough for the lung tumor to be surgically removed, and who have a […]
A study published in the journal Cell Stem Cell revealed how aging can cause lung regeneration to go awry, which can potentially lead to lung cancer and other diseases.
AstraZeneca and Daiichi Sankyo’s Enhertu helped patients with three different types of cancer live longer in trials, pointing to potential broader use of the breast cancer treatment.
The U.S. Food and Drug Administration approved Tecentriq as a standalone therapy for an advanced form of lung cancer.
The American Lung Association announced a $25 million initiative to support the fight against COVID-19, as well as future viral pandemics.
The U.S. Food and Drug Administration approved Boehringer Ingelheim’s Ofev (nintedanib) for patients with chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype.
The U.S. Food and Drug Administration granted Breakthrough Therapy designation to Genentech’s Esbriet as a potential treatment for adults with unclassifiable interstitial lung disease (uILD) as the Roche subsidiary looks to expand the drug’s indications.
Shares of Insmed skyrocketed after the company posted positive Phase II results for INS1007 as a potential treatment for adults with non-cystic fibrosis bronchiectasis (NCFBE).